• EpiQMAx GmbH
  • Am Klopferspitz 19
  • 82152 Planegg/Martinsried
  • Germany
  • Phone: +49 (0)89/70 93 93 16
  • Fax: +49 (0)89/218 071 601
  • moc.xamqipe@ofni

v.l.n.r.: Dr. Victor Solis, Geschäftsführer / Managing Director;
Dr. Moritz Völker-Albert, Geschäftsführer / Managing Director

About EpiQMAx

EpiQMAx is an innovative spin-off from the Biomedical Center in Munich. Based on the technology of mass spectrometry, EpiQMAx has been analyzing post-translational modifications of proteins since 2018. At the beginning of its foundation, the start-up focused on the analysis of epigenetic modifications and has developed a platform technology that includes a sample preparation KIT, mass spectrometry analysis and data visualization. EpiQMAx has thus created the basis on which the company has managed to publish clinical data on this topic. EpiQMAx has been expanding its portfolio since 2020 and offers analyzes of post-translational modifications of cellular and recombinant proteins. At its headquarter at the IZB, the company perates a state-ofthe-art mass spectrometer, that enables extensive screening of “epi-proteomes”.

What is your motivation?

We founded EpiQMAx GmbH in 2018 to translate research findings quickly and precisely into clinical applications. Our main motivation is to decipher epigenetic mechanisms in various diseases because we are convinced that epigenetics is the key for further development of personalized medicine. With this goal in mind, we want to make EpiQMAx the best CRO for epigenetic and epi-proteomic projects in Europe. Therefore, we are driven daily by exciting processes, a variety of tasks and the immediate feedback from our customers. So far, the IZB has played a decisive part in our journey. Since moving in 2019, we have been able to build strong alliances with many local companies. In this respect, we hope that we can continue to expand and grow at this location.

“With its strategic location on the Martinsried campus, the IZB offers an outstanding opportunity to found a company in the vicinity of science and industry.”

Dr. Moritz Völker-Albert
Geschäftsführer / Managing Director

EpiQMAx is an innovative spin-off from the BioMedical Center in Munich. Based on the technology of mass spectrometry, EpiQMAx has been analyzing post-translational modifications of proteins since 2018. At the beginning of its foundation, the start-up focused on the analysis of epigenetic modifications. and has developed a platform technology that includes a sample preparation KIT, mass spectrometry analysis and data visualization. EpiQMAx has thus created the basis on which the company has managed to publish clinical data on this topic.

EpiQMAx has been expanding its portfolio since 2020 and offers analyzes of post-translational modifications of cellular and recombinant proteins. At its headquarters at the IZB, the company operates a state-of-the-art mass spectrometer that enables extensive screening of “epi-proteomes”.